Oncogenically active MYD88 mutations in human lymphoma.

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Activated B-cell-like (ABC) diffuse large B-cell lymphoma (DLBCL) is a challenging subtype with limited curative options.
• Constitutive nuclear factor (NF)-κB and JAK kinase signaling pathways are crucial for ABC DLBCL cell survival.
• The precise genetic underpinnings of this aberrant signaling remain incompletely understood.

Purpose of the Study:

• To investigate the role of the MYD88 adaptor protein in ABC DLBCL pathogenesis.
• To identify and characterize oncogenic mutations in MYD88 within ABC DLBCL tumors.
• To elucidate the functional consequences of MYD88 mutations on signaling pathways and cell survival.

Main Methods:

• RNA interference screening to assess the essentiality of MYD88, IRAK1, and IRAK4 for ABC DLBCL survival.
• High-throughput RNA resequencing to identify mutations in MYD88.
• Functional assays to evaluate the impact of MYD88 mutations on protein complex assembly, kinase activity, and downstream signaling.

Main Results:

• MYD88 and associated kinases IRAK1/IRAK4 are essential for ABC DLBCL cell survival.
• Recurrent oncogenic mutations in the MYD88 Toll/IL-1 receptor (TIR) domain were identified in ABC DLBCL.
• The L265P substitution in MYD88 was found in 29% of ABC DLBCL tumors and acts as a gain-of-function mutation, promoting constitutive signaling and cell survival.
• MYD88 mutations were also observed in other lymphoma subtypes, including mucosa-associated lymphoid tissue lymphoma.

Conclusions:

• MYD88 signaling pathway is integral to ABC DLBCL pathogenesis.
• Gain-of-function MYD88 mutations, like L265P, drive oncogenesis by activating NF-κB and JAK/STAT3 pathways.
• Targeting IRAK4 kinase and other components of the MYD88 pathway presents a promising therapeutic strategy for MYD88-mutated DLBCL.